- Trials with a EudraCT protocol (381)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
381 result(s) found for: Hepatitis D.
Displaying page 6 of 20.
EudraCT Number: 2011-002413-11 | Sponsor Protocol Number: PRI01C | Start Date*: 2012-02-07 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza ty... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004978-26 | Sponsor Protocol Number: 73763989PAHPB2005 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, randomized, open-label, multicenter study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide a... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016635-36 | Sponsor Protocol Number: 113615 | Start Date*: 2010-03-04 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2,... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Primary and booster immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, serogroup C meningoc... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003538-11 | Sponsor Protocol Number: 1220.5 | Start Date*: 2008-10-01 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... | |||||||||||||
Medical condition: chronic hepatitis C infection of genotype 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) NL (Completed) PT (Completed) GB (Completed) AT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020387-38 | Sponsor Protocol Number: AI452-005 | Start Date*: 2010-12-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004221-25 | Sponsor Protocol Number: PRI02C | Start Date*: 2013-03-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur MSD | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase 3 open-label study to evaluate the immunogenicity and safety of a mixed (HEXA/PENTA/HEXA) primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel® at 4 month... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy infants greater than or equal to 46 days and less than or equal to 74 days of age on the day of inclusion | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001449-93 | Sponsor Protocol Number: 110031 | Start Date*: 2015-06-17 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, observer-blind follow-up study with two groups to assess the reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine (GSK1024850... | ||
Medical condition: Healthy volunteers (Booster immunization of healthy children previously primed with three doses of pneumococcal conjugate vaccine or a two-dose catch-up immunization in unprimed children previously... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-012460-14 | Sponsor Protocol Number: 112980 | Start Date*: 2010-05-03 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paed... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Primary and booster immunisation of healthy infants in the first two years of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, rotavirus and p... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) GB (Prematurely Ended) BE (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002585-12 | Sponsor Protocol Number: A3L00057 | Start Date*: 2020-08-03 | ||||||||||||||||
Sponsor Name:SANOFI PASTEUR | ||||||||||||||||||
Full Title: Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants | ||||||||||||||||||
Medical condition: Haemophilus influenzae type b immunisation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001956-31 | Sponsor Protocol Number: 2015-001956-31 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre. | |||||||||||||
Full Title: Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants | |||||||||||||
Medical condition: Patients with chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001344-22 | Sponsor Protocol Number: 116640 | Start Date*: 2013-02-19 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and ... | ||
Medical condition: Healthy volunteers (Hepatitis B surface antigen (HBsAg) vaccine administered in hepatitis B virus (HBV) naive adult subjects aged between 18 and 45 years old, inclusive, in good general health.) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-000943-26 | Sponsor Protocol Number: 115375 | Start Date*: 2011-05-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Completed) NO (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002543-92 | Sponsor Protocol Number: PO3523 | Start Date*: 2007-01-31 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) NL (Completed) PT (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021569-58 | Sponsor Protocol Number: 113948 | Start Date*: 2010-11-17 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001038-91 | Sponsor Protocol Number: NL57115 | Start Date*: 2016-11-18 |
Sponsor Name:Leiden university medical centre | ||
Full Title: A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis | ||
Medical condition: Autoimmune hepatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004129-27 | Sponsor Protocol Number: X06-MMRV-302 | Start Date*: 2006-12-13 |
Sponsor Name:Sanofi Pasteur MSD | ||
Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (... | ||
Medical condition: The study will involve healthy children. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005525-75 | Sponsor Protocol Number: SSAT052 | Start Date*: 2013-07-16 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genoty... | ||
Medical condition: Acute hepatitis C infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019057-17 | Sponsor Protocol Number: SPC3649-203 | Start Date*: 2010-07-13 |
Sponsor Name:Santaris Pharma A/S | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... | ||
Medical condition: Patients infected with chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) SK (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005547-24 | Sponsor Protocol Number: HXM01C | Start Date*: 2013-03-07 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur MSD | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase III open-label randomised study to evaluate the immunogenicity and safety of the concomitant administration of a new Hexavalent DTaP-IPV-HepB-PRP-T combined vaccine (Hexavalent vaccine) giv... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy infants 46 to 74 days of age (both inclusive) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003562-90 | Sponsor Protocol Number: VHCRP1405 | Start Date*: 2016-06-17 | ||||||||||||||||
Sponsor Name:The Kirby Institute - UNSW Australia | ||||||||||||||||||
Full Title: A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and... | ||||||||||||||||||
Medical condition: Chronic hepatitis C virus genotype 1 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
